(Q44646765)

5 December 2017

title

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension (English)

1 reference

5 December 2017

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80282-5

29 March 2024

4

Suzanne Oparil

1 reference

5 December 2017

Yves Lacourcière

2

1 reference

5 December 2017

Scott Krause

6

1 reference

5 December 2017

Barbara Roniker

7

1 reference

5 December 2017

Clement Maurath

8

1 reference

5 December 2017

Ellen D. Burgess

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14604739

29 March 2024

Luis M. Ruilope-Urioste

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14604739

29 March 2024

Jay H. Kleiman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14604739

29 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14604739

29 March 2024

publication date

1 September 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S0149291803802825?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80282-5

https://api.elsevier.com/content/article/PII:S0149291803802825?httpAccept=text/plain

29 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80282-5

29 March 2024

published in

Clinical Therapeutics

1 reference

5 December 2017

volume

25

1 reference

5 December 2017

issue

9

1 reference

5 December 2017

page(s)

2388-2404

1 reference

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Mineralocorticoids and cardiac fibrosis: the decade in review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Cardiovascular complications in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Arterial pressure, left ventricular mass, and aldosterone in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Aldosterone in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Aldosterone production is activated in failing ventricle in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

New frontiers in aldosterone/mineralocorticoid biology: a reemerging force in target organ damage and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Aldosterone as a mediator in cardiovascular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Hyperkalemia in Outpatients Using Angiotensin-Converting Enzyme Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980282-5

7 January 2021

Identification and role of aldosterone receptors in the cardiovascular system

13

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80282-5

29 March 2024

Identifiers

1 reference

5 December 2017

1 reference